1975P – Next Generation Sequencing (NGS) for the identification of PARP inhibitors’ predictive biomarkers

T. Floros, E. Papadopoulou, V. Metaxa-Mariatou, A. TsantikidiZ, G. Kapetsis, C. Florou-Chatzigiannidou, A. Meintani, N. Touroutoglou, I. Boukovinas4, F. Stavridi, C. Papadimitriou, D. Ziogas, M. Theochari, E. Timotheadou, A. Fassas, Z. Saridaki-Zoras, M. Ozdogan, U. Demirci, G. Nasioulas


The use of PARP inhibitors has been shown to be beneficial in tumors with BRCA1/2 mutations and has already been approved for patients with ovarian, breast, pancreatic and prostate cancer. The aim of the study was to access the utility of a multigene panel for the analysis of mutations in genes of the homologous recombination (HR) pathway as well as loss of heterozygosity (LOH), as predictors of treatment response.

Δείτε το poster εδώ

Leave a reply